title: Update on the Use and Treatment of Targeted Molecular Inhibitors for Locally Advanced and Metastatic Non-Melanoma Skin Cancers.
abstract: BACKGROUND
  Targeting specific molecular pathway inhibitors has provided a successful approach to the management of selected patients with advanced non-melanoma skin cancer (NMSC). Clinical trials and case studies have provided a rationale for their use in clinical settings.
  
  
  OBJECTIVE
  To review the current approaches to the use of targeted molecular inhibitors for locally advanced and metastatic squamous cell carcinoma, basal cell carcinoma, and dermatofibrosarcoma protuberans.
  
  
  METHODS
  Literature review of the current use of molecular inhibitors in the treatment of NMSCs, including case studies, reports, and clinical trials.
  
  
  CONCLUSIONS
  The development of molecular pathway inhibitors for the treatment of advanced and metastatic NMSC has increased survival rates and improved clinical outcomes in selected patients with advanced disease.
authors.affiliation: Department of Mohs Surgery, Mount Sinai Beth Israel Comprehensive Cancer Center, New York, New York.
authors.forename: Mercy
authors.initials: M
authors.lastname: Odueyungbo
authors.forename: Desiree
authors.initials: D
authors.lastname: Ratner
mesh_terms: D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D018223:Dermatofibrosarcoma / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D058990:Molecular Targeted Therapy / Q000009:adverse effects; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology